What is the appropriate treatment for vaginal Candida glabrata infection?

Treatment of Vaginal Candida glabrata Infection

For vaginal C. glabrata infection, intravaginal boric acid 600 mg daily for 14 days is the first-line treatment, particularly when standard azoles have failed or when azole resistance is suspected. 1, 2

Why C. glabrata Requires Different Treatment

C. glabrata accounts for 10-20% of recurrent vulvovaginal candidiasis cases and demonstrates intrinsic reduced susceptibility to standard-dose azole antifungals, including fluconazole. 2 This species is classified as "complicated" vulvovaginal candidiasis and requires specific treatment approaches distinct from C. albicans infections. 1, 2

Avoid fluconazole monotherapy for confirmed C. glabrata—it achieves response rates below 50% and is ineffective at standard doses. 2

Diagnostic Confirmation Before Treatment

Before initiating therapy, confirm the diagnosis through:

• Wet-mount preparation with 10% potassium hydroxide to demonstrate yeast cells, though C. glabrata does not form pseudohyphae or hyphae, making microscopic species identification unreliable. 1, 2
• Vaginal pH measurement should be 4.0-4.5 (normal range); higher pH suggests bacterial vaginosis or trichomoniasis instead. 1, 2
• Vaginal culture is essential for confirming C. glabrata because microscopy alone cannot reliably differentiate this species from other yeasts. 2

First-Line Treatment Regimen

Intravaginal boric acid 600 mg in a gelatin capsule, administered once daily for 14 days, is the primary recommended treatment. 1, 2 This regimen:

• Achieves clinical and mycological eradication in approximately 64-77% of patients. 2, 3, 4
• Receives a strong recommendation from the Infectious Diseases Society of America, despite low-quality underlying evidence. 1, 2
• Must be compounded by a pharmacist as gelatin capsules for vaginal use. 1
• Shows superior efficacy compared to single-dose fluconazole (72% vs. 33% mycological cure) in diabetic women with C. glabrata. 4

Complete the full 14-day course regardless of early symptom improvement to ensure mycological cure. 2 No advantage is observed in extending therapy beyond 14-21 days. 3

Alternative Treatment Options (When Boric Acid Fails or Is Unavailable)

If boric acid is ineffective, unavailable, or not tolerated, consider these alternatives in order:

1. Nystatin intravaginal suppositories 100,000 units daily for 14 days (strong recommendation, low-quality evidence). 1, 2

2. Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream, administered daily for 14 days (weak recommendation, low-quality evidence). 1, 2 This achieves 90% success in azole-refractory cases. 3

3. Non-fluconazole topical azoles for 7-14 days may be attempted before species confirmation, but they are significantly less effective for C. glabrata than for C. albicans. 2

Special Clinical Situations

Recurrent C. glabrata Infection

For maintenance therapy after initial cure, nystatin vaginal suppositories 100,000 units daily have been used successfully for long-term suppression. 2

Patients with Diabetes or Immunosuppression

Extended therapy (7-14 days) may be required for patients with uncontrolled diabetes or those receiving systemic corticosteroids. 2 Diabetic women show particularly poor response to standard fluconazole (28-33% cure rate). 4

HIV-Positive Women

Treatment approach should not differ based on HIV status; identical response rates are expected in both HIV-positive and HIV-negative women. 1, 2

Pregnancy

Topical azole therapy for 7 days is recommended in pregnant women, as oral fluconazole is contraindicated due to association with spontaneous abortion. 5

Important Caveats and Pitfalls

• Oil-based vaginal preparations (creams, suppositories) may weaken latex condoms and diaphragms, risking contraceptive failure. 2 Counsel patients accordingly.

• Partner treatment is not routinely recommended, as vulvovaginal candidiasis is not sexually transmitted. 2 However, male partners with symptomatic balanitis may benefit from topical antifungal therapy. 2

• Local side effects are uncommon with both boric acid and flucytosine regimens. 3

• Patients should return for follow-up if symptoms persist or recur after completing the treatment course to evaluate for alternative diagnoses or resistant infection. 2

• Voriconazole and posaconazole have been studied in small case series for fluconazole-resistant C. glabrata, but these are not guideline-recommended first-line options. 6